Overcoming unmet medical needs<Project Overview<Business-K-Health

Mission 2

Fundamental improvement of national disease patterns and public health through the development of cancer preventive vaccines, solutions for overcoming severe pain, and the identification of causes and development of treatments for rare and intractable diseases, ultimately leading to the conquest of unresolved diseases such as cancer and rare/intractable conditions.

CANDI
CANcer Detection Innovation
Development of highly sensitive and accessible early detection methods for the ten most prevalent cancers in the Korean population
View more
RACE
Rapid Advancement in Cold tumor Elimination
Ultra-Fast Validation and Development of Novel Drug Targets for Cold Tumors refractory to current treatment
View more
PAVE
Platform for Personalized neo-Antigen Vaccine Excellence

Establishing an optimization platform for developing patient-customized cancer vaccines

View more
HEART
Hope for Every child through Advanced Rare disease Therapies

Development of a patient-customized innovative treatment platform for pediatric rare diseases and N-of-1 clinical trials

View more
BEACON
Bridging Excellence in Advanced Cures for Orphan Needs

Patient-customized gene therapy to overcome vision loss from hereditary eye diseases

View more

Development of highly sensitive and accessible early detection methods for the ten most prevalent cancers in the Korean population

(CANDI : CANcer Detection Innovation)

Goal

Development of diagnostic technology with 90% sensitivity and 95% specificity through overcoming the limitations caused by the absence or trace levels of biomarkers in early-stage cancer.

Problem

Enhancement of early cancer detection rates and survival rates through simultaneous screening and diagnosis of the top 10 cancers among Koreans.

Innovation

Expansion and additional discovery of cancer biomarkers, along with a groundbreaking improvement in extraction, amplification, and analysis technologies for trace biomarkers in early-stage cancer.

Utilization

Securing additional biomarkers for cancer diagnosis and gradual improvement of early-stage cancer diagnostic technology.

PM Introduction

Kim, Youn Been PM View Profile

Overcoming Unmet Medical Needs such as Cancer, Rare, and Intractable Diseases

02-2288-6140
younbeen@khidi.or.kr

List

Ultra-Fast Validation and Development of Novel Drug Targets for Cold Tumors refractory to current treatment

(RACE : Rapid Advancement in Cold tumor Elimination)

Goal

Development of the first novel target-based anticancer drug in Korea.

Problem

Provision of new treatment options for representative refractory cancers that do not respond to existing targeted therapies or immunotherapies.

Innovation

Accelerated drug development, over 30% faster than conventional approaches, through the adoption and utilization of cutting-edge technologies such as AI, organoid models, and pharmacodynamic modeling and simulation, enabling faster Go/No-Go decisions.

Utilization

Identification of new druggable targets for refractory cancers and establishment of a new drug development platform through the application of cutting-edge drug discovery technologies.

PM Introduction

Kim, Youn Been PM View Profile

Overcoming Unmet Medical Needs such as Cancer, Rare, and Intractable Diseases

02-2288-6140
younbeen@khidi.or.kr

List

Establishing an optimization platform for developing patient-customized cancer vaccines

(PAVE : Platform for Personalized neo-Antigen Vaccine Excellenc)

Goal

Establishing and achieving optimization of an integrated platform of detailed technologies for
patient-personalized neoantigen-based cancer vaccines

Problem

Limitations of standard treatments due to individual cancer genetic mutations and
heterogeneity of the immune environment

Innovation

Improving and verifying AI-based personal neoantigen positivity prediction rates and establishing a pre-licensed on-demand PCV development platform for rapid cancer vaccine development

Utilization

Accelerating personalized cancer vaccine development and enhancing commercialization potential based on improving patient accessibility, manufacturing speed, and presenting target production costs

PM Introduction

Kim, Youn Been PM View Profile

Overcoming Unmet Medical Needs such as Cancer, Rare, and Intractable Diseases

02-2288-6140
younbeen@khidi.or.kr

List

Development of a patient-customized innovative treatment platform for pediatric rare diseases and N-of-1 clinical trials

(HEART: Hope for Every child through Advanced Rare disease Therapies)

Goal

Designing and verifying a patient-customized innovative treatment platform for pediatric rare diseases and treating pediatric rare disease patients through N-of-1 clinical trials

Problem

Urgent need for regulatory support and comprehensive challenges including patient rarity, disease heterogeneity due to genetic traits, diversity of mutations, low corporate investment, and difficulties in securing non-clinical models for rare diseases

Innovation

Developing platform therapeutics based on advanced innovative technology specific to patient genetic mutations and shifting the treatment paradigm through patient-customized N-of-1 clinical trials

Utilization

Expanding treatment opportunities for pediatric rare disease
patients and promoting the overcoming of rare diseases

PM Introduction

Park, Misun PM View Profile

Overcoming Unmet Medical Needs such as Cancer, Rare, and Intractable Diseases

02-2288-6141
mpark7@khidi.or.kr

List

Patient-customized gene therapy to overcome vision loss from hereditary eye diseases

(BEACON : Bridging Excellence in Advanced Cures for Orphan Needs)

Goal

Establishing strategies for clinical entry and commercialization of patient-customized gene therapies for hereditary eye diseases

Problem

Lack of patient-customized gene therapies for hereditary eye diseases prevalent in Koreans, high R&D costs, and challenging limitations in clinical entry and regulatory support

Innovation

Introducing a DNA-based, domestic patient- and mutation-specific, patient-customized treatment platform and accelerating clinical entry and commercialization

Utilization

Providing new treatment opportunities for patients with hereditary eye diseases
and improving the quality of life for patients with rare diseases

PM Introduction

Park, Misun PM View Profile

Overcoming Unmet Medical Needs such as Cancer, Rare, and Intractable Diseases

02-2288-6141
mpark7@khidi.or.kr

List